- Home
- BPTH vs CTHR Comparison
BPTH vs CTHR Comparison
Compare BPTH & CTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPTH
- CTHR
- Stock Information
- Founded
- BPTH 2007
- CTHR 1995
- Country
- BPTH United States
- CTHR United States
- Employees
- BPTH N/A
- CTHR N/A
- Industry
- BPTH Biotechnology: Pharmaceutical Preparations
- CTHR Consumer Specialties
- Sector
- BPTH Health Care
- CTHR Consumer Discretionary
- Exchange
- BPTH Nasdaq
- CTHR Nasdaq
- Market Cap
- BPTH 4.0M
- CTHR 4.1M
- IPO Year
- BPTH N/A
- CTHR 1997
- Fundamental
- Price
- BPTH $0.82
- CTHR $1.31
- Analyst Decision
- BPTH Strong Buy
- CTHR
- Analyst Count
- BPTH 2
- CTHR 0
- Target Price
- BPTH $30.00
- CTHR N/A
- AVG Volume (30 Days)
- BPTH 107.7K
- CTHR 14.5K
- Earning Date
- BPTH 11-15-2024
- CTHR 12-03-2024
- Dividend Yield
- BPTH N/A
- CTHR N/A
- EPS Growth
- BPTH N/A
- CTHR N/A
- EPS
- BPTH N/A
- CTHR N/A
- Revenue
- BPTH N/A
- CTHR $23,684,860.00
- Revenue This Year
- BPTH N/A
- CTHR $31.82
- Revenue Next Year
- BPTH N/A
- CTHR N/A
- P/E Ratio
- BPTH N/A
- CTHR N/A
- Revenue Growth
- BPTH N/A
- CTHR N/A
- 52 Week Low
- BPTH $0.61
- CTHR $1.18
- 52 Week High
- BPTH $12.40
- CTHR $4.90
- Technical
- Relative Strength Index (RSI)
- BPTH 40.36
- CTHR 41.96
- Support Level
- BPTH $0.74
- CTHR $1.26
- Resistance Level
- BPTH $0.85
- CTHR $1.38
- Average True Range (ATR)
- BPTH 0.09
- CTHR 0.10
- MACD
- BPTH -0.01
- CTHR 0.01
- Stochastic Oscillator
- BPTH 53.85
- CTHR 28.33
About BPTH Bio-Path Holdings Inc.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
About CTHR Charles & Colvard Ltd
Charles & Colvard Ltd manufactures, markets, and distributes finished jewellery which also includes moissanite gemstone in the jewellery market. The company sells jewels through two operating segments namely Online Channels segment and Traditional segment. It generates maximum revenue from the Online Channels segment. Online Channels segment which consists of e-commerce outlets including charlesandcolvard.com, moissaniteoutlet.com, third-party online marketplaces, drop-ship retail, and other pure-play, exclusively e-commerce outlets.